文献速递骨质疏松与代谢性骨病

SGLT2抑制剂对2型糖尿病患者骨折、骨密度及骨代谢标志物的影响:系统综述与荟萃分析

Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
PubMed 文献 · Osteoporos Int · 2023-09-11

该系统综述与荟萃分析纳入20项随机对照试验共12764例2型糖尿病患者,评估SGLT2抑制剂对骨折风险、骨密度及骨代谢标志物的影响。结果显示SGLT2抑制剂使用与骨折风险升高无显著关联(合并RR=1.21,95%CI[0.95,1.54]),对腰椎、股骨颈、全髋及桡骨远端骨密度和CTX、P1NP、PTH、钙、磷等骨代谢标志物均无显著影响。作者认为仍需进一步临床研究和更长随访期以得出更确定的结论。

要点

  • SGLT2抑制剂与2型糖尿病患者骨折风险升高无显著关联(合并RR=1.21,95%CI[0.95,1.54])。
  • SGLT2抑制剂对腰椎、股骨颈、全髋及桡骨远端骨密度变化均无显著影响。
  • SGLT2抑制剂对CTX、P1NP、PTH、钙、磷等骨代谢标志物均无显著影响。

核心结论

  • SGLT2抑制剂的使用与2型糖尿病患者骨折风险升高无显著关联(合并RR=1.21,95%CI[0.95,1.54])。
  • 作者认为仍需进一步临床研究和更长随访期以得出更确定的结论。

研究设计与样本

  • 系统综述与荟萃分析,纳入20项随机对照试验(RCTs),共涉及12764例患者。
  • 采用合并相对危险度(RR)及95%置信区间(CI)评估SGLT2抑制剂与骨折风险的关系。
  • 采用加权均数差(WMD)及95%CI探讨SGLT2抑制剂与骨密度及骨代谢标志物的相关性。

主要发现

  • SGLT2抑制剂与骨折风险升高无显著关联(合并RR=1.21,95%CI[0.95,1.54],I²=22%)。
  • SGLT2抑制剂对腰椎骨密度变化无显著影响(WMD=-0.02,95%CI[-0.38,0.34])。
  • SGLT2抑制剂对股骨颈骨密度变化无显著影响(WMD=0.11,95%CI[-0.28,0.50])。
  • SGLT2抑制剂对全髋骨密度变化无显著影响(WMD=-0.20,95%CI[-0.41,0.01])。
  • SGLT2抑制剂对桡骨远端骨密度变化无显著影响(WMD=-0.20,95%CI[-0.62,0.22])。

关键数值与推荐

  • 骨折风险:合并RR=1.21,95%CI[0.95,1.54],I²=22%。
  • 腰椎骨密度:WMD=-0.02,95%CI[-0.38,0.34]。
  • 股骨颈骨密度:WMD=0.11,95%CI[-0.28,0.50]。
  • 全髋骨密度:WMD=-0.20,95%CI[-0.41,0.01]。
  • 桡骨远端骨密度:WMD=-0.20,95%CI[-0.62,0.22]。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为仍需进一步临床研究和更长随访期以得出更确定的结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This meta-analysis aims to evaluate the impact of Sodium Glucose Transporter 2 (SGLT2) inhibitors on fractures, bone mineral density (BMD), and bone metabolism markers in type 2 diabetes mellitus (T2DM) patients. Pooled relative risk (RR) with 95% confidence interval (CI) assessed the relationship between SGLT2 inhibitors and fracture risk. Weighted mean difference (WMD) with 95% CI explored the correlation between SGLT2 inhibitors and BMD, as well as bone metabolism markers. A total of 20 randomised controlled trials (RCTs) involving 12,764 patients were analysed. No significant association emerged between SGLT2 inhibitor use and elevated fracture risk (pooled RR = 1.21, 95% CI [0.95, 1.54], I2 = 22%). Furthermore, SGLT2 inhibitors exhibited no substantial effects on BMD changes at the lumbar spine (WMD = -0.02, 95% CI [-0.38, 0.34]), femoral neck (WMD = 0.11, 95% CI [-0.28, 0.50]), total hip (WMD = -0.20, 95% CI [-0.41, 0.01]), and distal forearm (WMD = -0.20, 95% CI [-0.62, 0.22]). Similarly, no notable impact of SGLT2 inhibitors on bone metabolism markers, including CTX (WMD = 0.04, 95% CI [-0.02, 0.09]), P1NP (WMD = 1.06, 95% CI [-0.44, 2.57]), PTH (WMD = 0.34, 95% CI [-0.07, 0.75]), calcium (WMD = 0.01, 95% CI [-0.02, 0.04]), and phosphate (WMD = 2.37, 95% CI [-0.76, 5.49]). The findings suggest that the utilization of SGLT2 inhibitors is not significantly linked to an elevated risk of fractures in individuals with T2DM. However, further clinical investigations and extended follow-up periods are warranted to establish more conclusive determinations.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Wang X, Zhang F, Zhang Y, et al. Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Osteoporos Int. 2023. PMID: 37695339. doi:10.1007/s00198-023-06908-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。